GlassScriptPhysician profile
Erika Smith Mccarty
NPI 1780046102
$4,582.98
in general payments reported to CMS, 2019-2025
26 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $538 · 2022: $501 · 2023: $864 · 2024: $1,430 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,466 · Travel and Lodging: $78.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,465.51 |
| Travel and Lodging | $78.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $882.14 | 2021-2025 | Aveir, Jot Dx, Cardiomems |
| Merck Sharp & Dohme LLC | $644.13 | 2021-2025 | Verquvo, Keytruda, Capvaxive |
| Boston Scientific Corporation | $473.80 | 2021-2025 | Watchman Access System, Bodyguardian, Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $417.66 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.60 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $245.70 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $234.06 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Medtronic, INC. | $207.28 | 2021-2025 | Linq II |
| Philips North America LLC | $144.23 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Pfizer INC. | $137.19 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $103.28 | 2022-2024 | Onpattro |
| Biosense Webster, INC. | $101.67 | 2022-2023 | Carto 3 |
| Novo Nordisk INC | $100.30 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $89.27 | 2023-2025 | |
| Amgen INC. | $83.14 | 2023-2025 | Repatha, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.08 | 2024-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $67.50 | 2024 | |
| Edwards Lifesciences Corporation | $58.84 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cvrx, INC. | $49.67 | 2022-2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $38.04 | 2025 | |
| Abiomed | $28.95 | 2025 | |
| Stryker Corporation | $28.93 | 2024 | Spy-Phi System |
| Cardiva Medical, INC. | $23.99 | 2025 | Savvywire |
| Daiichi Sankyo INC. | $23.75 | 2024 | Injectafer |
| Biotronik INC. | $23.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.11 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.